Skip to content

Prevention of Hand Eczema Among Workers in the Fishing Industry in Greenland

Prevention of Hand Eczema Among Workers in the Fishing Industry in Greenland: an Intervention Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06997393
Acronym
HEFIG
Enrollment
70
Registered
2025-05-30
Start date
2025-06-10
Completion date
2025-12-31
Last updated
2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand Eczema

Brief summary

This study aims to investigate the effect of a prevention programme on hand eczema among workers in the Greenlandic fishing industry. This is a non-randomised clinical trial including employees at four of Royal Greenland's fish processing facilities in Greenland.

Interventions

The prevention programme consists of a validated educational video and training in the basic recognition and prevention of hand eczema.

Sponsors

LEO Foundation
CollaboratorUNKNOWN
University of Copenhagen
CollaboratorOTHER
Greenland University
CollaboratorUNKNOWN
Government of Greenland, Agency for Health and Prevention
CollaboratorUNKNOWN
Bispebjerg Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Employee in Royal Greenland, a state-owned company and one of the largest seafood enterprises in the world * Written informed consent

Exclusion criteria

* Age below 18 years * Inability to understand the Greenlandic, Danish or English language * Pregnancy * Other chronic skin diseases on the hands * Receiving immunomodulatory therapies

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in knowledge of hand eczema at 3 monthsFrom enrollment to the end of intervention at 12 weeksKnowledge of hand eczema measured by a self-reported questionnaire
Change from baseline in clinical severity of hand eczema at 3 monthsFrom enrollment to the end of intervention at 12 weeksClinical severity of hand eczema measured by Hand Eczema Severity Index (HECSI). The HECSI score ranges from 0 to 360, with higher scores reflecting greater disease severity.

Secondary

MeasureTime frameDescription
Change from baseline in the number of self-reported days with absence from work due to hand eczema at 3 monthsFrom enrollment to the end of intervention at 12 weeksThe number of self-reported days with absence from work due to hand eczema measured by a questionnaire-based interview.
Change from baseline in patient-reported quality of life at 3 monthsFrom enrollment to the end of intervention at 12 weeksPatient-reported quality of life measured by Hand Eczema Impact Scale (HEIS). The HEIS is a validated 9-item questionnaire that measure the impact of hand eczema on patients' quality of life, based on recall over the past week. Domains include proximal daily activity limitations, embarrassment with the appearance of the hands, frustration with chronic hand eczema, sleep, work, and physical functioning. Each item is scored on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The HEIS score is the average of the 9 items.
Change from baseline in the availability of protective equipment at 3 monthsFrom enrollment to the end of intervention at 12 weeksThe availability of protective equipment (protective gloves, cotton undergloves, moisturisers, and disinfectants) at the workplace measured by a questionnaire-based interview.
Change from baseline in the number of participants being forced to change their job due to hand eczema at 3 monthsFrom enrollment to the end of intervention at 12 weeksThe number of participants being forced to change their job due to hand eczema measured by a questionnaire-based interview.
Change from baseline in Patient Global Assessment of Disease Severity (PaGA) at 3 monthsFrom enrollment to the end of intervention at 12 weeksThe PaGA rates the severity of the patient's global disease assessed by the patient and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

Countries

Greenland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026